ROS1 and non-small cell lung carcinoma: In non-small-cell lung carcinoma, patients with the TPD52L1-ROS1 fusion variant [i.e., fusion of the coiled-coil domain of TPD52L1 and kinase domain of ROS1 (64)] could benefit from treatment regimens incorporating a ROS1 inhibitor (65).